Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.

被引：0
|
作者：
Nikitas, John
Lam, Ethan C.
Booker, Kiara M.
Fendler, Wolfgang P.
Eiber, Matthias
Hadaschik, Boris A.
Herrmann, Ken
Hirmas, Nader
Lanzafame, Helena
Stuschke, Martin
Czernin, Johannes
Steinberg, Michael L.
Nickols, Nicholas George
Kishan, Amar Upadhyaya
Calais, Jeremie
机构：
[1] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Ahmanson Translat Theranost Div, Los Angeles, CA USA
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Nucl Med, Essen, Germany
[4] Tech Univ Munich, Dept Nucl Med, Munich, Germany
[5] Univ Duisburg Essen, Dept Urol, Essen, Germany
[6] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[7] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany
[8] Univ Duisburg Essen, Univ Med Essen, Dept Radiotherapy, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
613-615-646-3281-7408-2399; 261-137; 283-183-180; 613-545; 261-436-2730; 14; 6; 3; 3617; 2;
D O I：
10.1200/JCO.2024.42.4_suppl.291
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [1] Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer
    Nikitas, John
    Lam, Ethan
    Booker, Kiara
    Fendler, Wolfgang
    Eiber, Matthias
    Hadaschik, Boris
    Herrmann, Ken
    Hirmas, Nader
    Lanzafame, Helena
    Stuschke, Martin
    Czernin, Johannes
    Steinberg, Michael
    Nickols, Nicholas
    Kishan, Amar
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [2] Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.
    Calais, Jeremie
    Zhu, Shaojun
    Hirmas, Nader
    Eiber, Matthias
    Hadaschik, Boris A.
    Stuschke, Martin
    Herrmann, Ken
    Czernin, Johannes
    Kishan, Amar Upadhyaya
    Nickols, Nicholas George
    Elashoff, David
    Fendler, Wolfgang Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
    Jeremie Calais
    Shaojun Zhu
    Nader Hirmas
    Matthias Eiber
    Boris Hadaschik
    Martin Stuschke
    Ken Herrmann
    Johannes Czernin
    Amar U. Kishan
    Nicholas G. Nickols
    David Elashoff
    Wolfgang P. Fendler
    BMC Cancer, 21
  • [4] Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
    Calais, Jeremie
    Zhu, Shaojun
    Hirmas, Nader
    Eiber, Matthias
    Hadaschik, Boris
    Stuschke, Martin
    Herrmann, Ken
    Czernin, Johannes
    Kishan, Amar U.
    Nickols, Nicholas G.
    Elashoff, David
    Fendler, Wolfgang P.
    BMC CANCER, 2021, 21 (01)
  • [5] Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study Protocol.
    Calais, Jeremie
    Zhu, Shaojun
    Hrimas, Nader
    Eiber, Matthias
    Hadaschik, Boris
    Stuschke, Martin
    Herrmann, Ken
    Czernin, Johannes
    Kishan, Amar U.
    Nickols, Nicholas G.
    Elashoff, David
    Fendler, Wolfgang
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
    Nikitas, John
    Lam, Ethan
    Booker, Kiara Adame
    Fendler, Wolfgang P.
    Eiber, Matthias
    Hadaschik, Boris
    Herrmann, Ken
    Hirmas, Nader
    Lanzafame, Helena
    Stuschke, Martin
    Czernin, Johannes
    Steinberg, Michael L.
    Nickols, Nicholas G.
    Kishan, Amar U.
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (07) : 1076 - 1079
  • [7] The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer
    Hagens, Marinus J.
    Luining, Wietske I.
    Jager, Auke
    Donswijk, Maarten L.
    Cheung, Zing
    Wondergem, Maurits
    Oprea-Lager, Daniela E.
    Vis, Andre N.
    van Leeuwen, Pim J.
    van der Poel, Henk G.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (08) : 1238 - 1243
  • [8] Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial
    Roberts, Matthew
    Roberts, Natasha
    Harley, Simon
    Cullen, Karla
    Pelecanos, Anita
    Vela, Ian
    Yaxley, John
    Kuchel, Anna
    Dhiantravan, Nattakorn
    Thomas, Paul
    Pattison, David
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 75 - 75
  • [9] PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer
    Cook, Gary J. R.
    Kulkarni, Meghana
    Warbey, Victoria S.
    BJU INTERNATIONAL, 2019, 124 (03) : 357 - 358
  • [10] Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection
    Droghetti, Matteo
    Bianchi, Lorenzo
    Presutti, Massimiliano
    Vetrone, Luigia
    Farolfi, Andrea
    Mei, Riccardo
    Giunchi, Francesca
    Degiovanni, Alessio
    Mottaran, Angelo
    Piazza, Pietro
    Cangemi, Danilo
    Castellucci, Paolo
    D'Errico, Antonietta
    Schiavina, Riccardo
    Brunocilla, Eugenio
    Fanti, Stefano
    FRONTIERS IN ONCOLOGY, 2024, 14
12345